Lucid Diagnostics Q2 2026: $1.5M revenue, 2,770 EsoGuard tests, first LBM coverage policy

Lucid Diagnostics Inc.

Q2 2026 EsoGuard revenue of $1.5M; 2,770 EsoGuard tests processed during the quarter.
GAAP net loss ~$14.7M ($0.08/share) incl. $3.0M deemed preferred stock dividend; non-GAAP adjusted loss ~$10.9M ($0.06/share).
Operating expenses ~$14.3M, including $1.7M stock-based compensation; cash $33.4M at June 30, 2026 vs $34.7M at Dec 31, 2025.
Secured first laboratory benefit manager coverage policy from Concert (acquired by Lyric) recognizing EsoGuard as medically necessary for eligible patients.
Developed health economic model showing improved clinical outcomes and cost-effectiveness; awaiting draft Medicare coverage policy for EsoGuard.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.